fbpx

News

Lundbeckfonden Emerge News

NMD Pharma develops new treatments, improving the signaling of the nerves to the muscles, to patients suffering from orphan motor neuron diseases including Myasthenia Gravis, Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). The company has identified a novel disease target and developed new small molecule drug-like compounds effectively increasing neuromuscular transmission. In models...
 IO Biotech today announced the successful completion of a ?11 million Series A financing round. Participants were new investor Lundbeckfonden as well as existing investor Novo A/S.
Lundbeck Foundation is investing a further DKK 15 million in Aarhus-based Insusense Therapeutics, a biotech company which develops new drugs for the treatment of type 2 diabetes and obesity.
Lundbeck Foundation has decided to invest DKK 300 million in Danish biotech companies over the next four years. The funds will be invested by Lundbeckfond Emerge with the aim of generating a portfolio of five active companies over the course of a couple of years.
1 2 3

Lundbeckfonden Emerge

News

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology
13. January 2021
The Lundbeck Foundation increases its commitment to IO Biotech
12. January 2021
The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma
15. December 2020